Abstract: This invention relates to genetically modified gram-negative bacteria specifically designed to release engineered Outer Membrane Vesicles (OMVs) carrying Coronavirus (poly)peptides. The invention further provides methods for the preparation of the OMVs, immunogenic compositions containing them and the use thereof as vaccines for the prophylaxis and treatment of SARS-CoV2 infections.

Abstract: There is disclosed a method for the co-expression of multi-antigens in bacterial outer membrane vesicles, immunogenic compositions containing the isolated vesicles and the use thereof for the prevention or treatment of bacterial infections.

Abstract: The invention relates to gram-negative bacteria carrying gene-inactivating mutations that cause deletion of proteins belonging to the OMV proteome, to Outer Membrane Vesicles (OMVs) produced by these bacteria and immunogenic compositions thereof.

Abstract: The present invention provides means and products for the stimulation of an immune response against tumors in a subject in need thereof. More specifically the invention provides immunogenic compositions containing bacterial outer membrane vesicles loaded with tumor antigens, fusion proteins comprising a bacterial protein and a tumor antigen, and isolated bacterial outer membrane vesicles (OMVs) containing said fusion proteins. The fusion proteins, OMVs and immunogenic compositions according to the invention are used in the prevention and treatment of tumors.

Abstract: There are disclosed fusion proteins comprising the bacterial protein FhuD2 and one or more copies of a heterologous polypeptide, polynucleotides and expression vectors encoding the fusion proteins and bacterial outer membrane vesicles containing them. Other aspects of the invention regard immunogenic compositions comprising the outer membrane vesicles and their use in the prevention or treatment of tumors.

Abstract: Newly identified proteins as markers for the detection of colon, ovary, kidney, esophagus and prostate tumors, or as therapeutic targets for their treatment; affinity ligands and particularly antibodies capable of selectively interacting with the tumor markers and methods for tumor diagnosis and therapy using such antibodies.

Abstract: Newly identified proteins as markers for the detection of ovary tumors, or as therapeutic targets for treatment thereof; affinity ligands capable of selectively interacting with the newly identified markers, methods for tumor diagnosis and therapy using the same.

Abstract: The present invention provides means and products for the stimulation of an immune response against tumors in a subject in need thereof. More specifically the invention provides immunogenic compositions containing bacterial outer membrane vesicles loaded with tumor antigens, fusion proteins comprising a bacterial protein and a tumor antigen, and isolated bacterial outer membrane vesicles (OMVs) containing said fusion proteins. The fusion proteins, OMVs and immunogenic compositions according to the invention are used in the prevention and treatment of tumors.

Abstract: Newly identified proteins as markers for the detection of ovary tumors, or as therapeutic targets for treatment thereof; affinity ligands capable of selectively interacting with the newly identified markers, methods for tumor diagnosis and therapy using the same.

Abstract: Newly identified proteins as markers for the detection of breast tumors, or as therapeutic targets for treatment thereof; affinity ligands capable of selectively interacting with the newly identified markers, as well as methods for tumor diagnosis and therapy using such ligands.

Abstract: Newly identified proteins as markers for the detection of colon, ovary, kidney, esophagus and prostate tumors, or as therapeutic targets for their treatment; affinity ligands and particularly antibodies capable of selectively interacting with the tumor markers and methods for tumor diagnosis and thereapy using such antibodies.

Abstract: The invention relates to pharmaceutical compositions comprising animal vesicles and bacterial vesicles, and to methods for preparing and using them. Animal vesicles and bacterial vesicles fuse to form immunogenic pharmaceutical compositions. The animal vesicular component provides a specific adaptive immune response and the bacterial vesicular component provides adjuventicity.

Abstract: Newly identified proteins as markers for the detection of prostate tumors, or as targets for their therapeutic treatment, affinity ligands capable of selectively interacting with said markers as well as methods for tumor diagnosis and therapy using the same.

Abstract: Newly identified proteins as markers for the detection of prostate tumors, or as targets for their therapeutic treatment, affinity ligands capable of selectively interacting with said markers as well as methods for tumor diagnosis and therapy using the same.

Abstract: Newly identified proteins as markers for the detection of breast, colon, lung and ovary tumors, or as therapeutic targets for their treatment, affinity ligands capable of selectively interacting with the newly identified markers and methods for tumor diagnosis and therapy using such ligands.

Abstract: Newly identified proteins as markers for the detection of colon and rectal tumors, or as therapeutic targets for treatment thereof; affinity ligands capable of selectively interacting with the newly identified markers, as well as methods for tumor diagnosis and therapy using such ligands.

Abstract: Newly identified proteins as markers for the detection of breast tumors, or as therapeutic targets for treatment thereof; affinity ligands capable of selectively interacting with the newly identified markers, as well as methods for tumor diagnosis and therapy using such ligands.

Abstract: Newly identified proteins as markers for the detection of ovary tumors, or as therapeutic targets for treatment thereof; affinity ligands capable of selectively interacting with the newly identified markers, methods for tumor diagnosis and therapy using the same.

Abstract: Newly identified proteins as markers for the detection of prostate tumors, or as targets for their therapeutic treatment, affinity ligands capable of selectively interacting with said markers as well as methods for tumor diagnosis and therapy using the same.

Abstract: Newly identified proteins as markers for the detection of lung tumors, or as therapeutic targets for their treatment, affinity ligands capable of selectively interacting with the newly identified markers and methods for tumor diagnosis and therapy using such ligands.